新发现的肽激素经受体GPRC6A抑制肠道脂肪吸收并改善NAFLD
研究鉴定出一种小鼠循环十五肽——代谢素(MTL),可结合GPRC6A。在高脂饮食小鼠中,腹腔或口服MTL均改善NAFLD和胰岛素抵抗,机制为抑制肠道神经降压素分泌,经AMPK通路抑制甘油三酯吸收,并诱导GLP-1分泌。
要点
- MTL经GPRC6A抑制肠道神经降压素分泌,减少甘油三酯吸收。
- 腹腔或口服MTL均改善高脂饮食小鼠NAFLD和胰岛素抵抗。
- MTL诱导GLP-1分泌,具NAFLD治疗潜力。
核心结论
- 口服或腹腔注射MTL通过抑制脂质吸收和胰岛素抵抗显著改善小鼠NAFLD症状。
- MTL可能是治疗NAFLD的潜在候选药物。
研究设计与样本
- 采用生物信息学鉴定小鼠循环十五肽MTL。
- 用配体-受体结合、受体内化、BRET和Nano ITC研究MTL与GPRC6A结合。
- 高脂饮食野生型小鼠腹腔注射或灌胃MTL进行体内研究。
主要发现
- 体外实验证实MTL结合GPRC6A,骨钙素与GPRC6A相互作用。
- 腹腔和口服MTL均显著改善小鼠NAFLD和胰岛素抵抗。
- MTL与肠道GPRC6A作用抑制神经降压素分泌,经AMPK通路抑制甘油三酯吸收而不影响胆固醇吸收。
- MTL治疗诱导GLP-1分泌。
临床怎么用
- MTL有望成为NAFLD治疗候选药物,但尚需临床研究验证。
局限性
- 研究仅在小鼠模型中进行,尚未在人体验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Circulating peptides and G protein-coupled receptors (GPCRs) have gained much attention because of their biofunctions in metabolic disorders including obesity and non-alcoholic fatty liver disease (NAFLD). Herein, we aimed to characterize the role and therapeutic potential of a newly identified peptide hormone in NAFLD. METHODS: Using bioinformatics, we identified a murine circulating pentadecapeptide flanked by potential convertase cleavage sites of osteocalcin (OCN), which we named 'metabolitin (MTL)'. We used ligand-receptor binding, receptor internalization, bioluminescence resonance energy transfer and Nano isothermal titration calorimetry assays to study the binding relationship between MTL and GPRC6A. For in vivo biological studies, wild-type mice kept on a high-fat diet (HFD) were injected or gavaged with MTL to study its function in NAFLD. RESULTS: We confirmed that MTL binds to GPRC6A and OCN interacts with GPRC6A using in vitro biological studies. Both intraperitoneal and oral administration of MTL greatly improved NAFLD and insulin resistance in a mouse model. Interacting with GPRC6A expressed in intestines, MTL can significantly inhibit intestinal neurotensin secretion, which in turn inhibits triglyceride but not cholesterol gut absorption, mediated by the 5'AMP-activated protein kinase pathway. In addition, glucagon like peptide-1 secretion was induced by MTL treatment. CONCLUSIONS: Oral or intraperitoneal MTL significantly improves the symptoms of NAFLD by inhibiting lipid absorption and insulin resistance. MTL could be a potential therapeutic candidate for the treatment of NAFLD. LAY SUMMARY: A novel murine peptide hormone, herein named 'metabolitin', inhibits fatty acid absorption and improves systemic insulin resistance in a murine model of obesity and non-alcoholic fatty liver disease. Thus, metabolitin has therapeutic potential for the treatment of patients with non-alcoholic fatty liver disease.
引用
- Teng B, Huang C, Cheng CL, et al. Newly identified peptide hormone inhibits intestinal fat absorption and improves NAFLD through its receptor GPRC6A. J Hepatol. 2020. PMID: 32147363. doi:10.1016/j.jhep.2020.02.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。